Current Industry Best Practice on in-use Stability and Compatibility Studies for Biological Products

被引:15
作者
Blumel, Markus [1 ]
Liu, Jing [2 ]
de Jong, Isabella [3 ]
Weiser, Sarah [4 ]
Fast, Jonas [5 ]
Litowski, Jennifer [6 ]
Shuman, Melissa [7 ]
Mehta, Shyam B. [8 ]
Amery, Leanne [9 ]
Tan, David Cheng Thiam [10 ]
Jia, Feng [11 ]
Shekhawat, Dushyant [12 ]
Dagallier, Camille [13 ]
Emamzadeh, Mina [9 ]
Medina, Annette [14 ]
Santos, Camilla [15 ]
Gasser, Florian [16 ]
Urban, Christian [17 ]
机构
[1] Novartis Pharm AG, Biol Analyt Dev, Lichtstr 35, CH-4056 Basel, Switzerland
[2] Seagen Inc, Pharmaceut Sci, 21717 30th Dr SE,Bldg 3, Bothell, WA 98021 USA
[3] Genentech Inc, Pharmaceut Dev, 1 DNA Way, South San Francisco, CA 94080 USA
[4] Pfizer Biotherapeut Pharmaceut Sci, 1 Burtt Rd, Andover, MA 01810 USA
[5] Hoffmann La Roche Ltd, Pharmaceut Dev & Supplies, PTD Biol Europe, Grenzacherstr 124, CH-4070 Basel, Switzerland
[6] Amgen Inc, Proc Dev, 360 Binney St, Cambridge, MA 02141 USA
[7] GSK, Strateg External Dev, Sterile Drug Prod Operat, 1250 S Collegeville Rd, Collegeville, PA 19426 USA
[8] Teva Branded Pharmaceut Prod R&D Inc, Drug Metab & Pharmacokinet, 145 Brandywine Pkwy, W Chester, PA 19380 USA
[9] AstraZeneca, Dosage Form Design & Dev, Aaron Klug Bldg,Granta Pk, Cambridge CB21 6GH, Cambs, England
[10] AbbVie Inc, N Chicago, IL USA
[11] Biogen Biol Drug Prod, Cambridge, MA 02142 USA
[12] Eli Lilly & Co, Bioprod Res & Dev, Indianapolis, IN 46285 USA
[13] Sanofi, Biol Drug Prod Dev, 1 Impasse Ateliers, F-94403 Vitry Sur Seine, France
[14] AstraZeneca, Dosage Form Design & Dev, One Medimmune Way, Gaithersburg, MD 20878 USA
[15] Amgen Inc, Prod Qual, 40 Technol Way, West Greenwich, RI 02817 USA
[16] Novartis Pharm AG, Biol Analyt Dev, Biochemiestr 10, A-6336 Langkampfen, Austria
[17] Sanofi, Biol Drug Prod Dev, Industriepark Hochst, D-65926 Frankfurt, Germany
关键词
Protein delivery; Analytical chemistry; Polymeric drug delivery system(s); Regulatory science; MONOCLONAL-ANTIBODIES; PROTEIN FORMULATIONS; TRANSFER DEVICES; INFUSION BAGS; LINE FILTERS; STORAGE; DRUG; PERSPECTIVE; PARTICLES; GLYCATION;
D O I
10.1016/j.xphs.2023.05.002
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Evaluating the in-use stability of a biological product including its compatibility with administration components allows to define handling instructions and potential hold times that retain product quality during dose preparation and administration. The intended drug product usage may involve the dilution of drug formulation into admixtures for infusion and exposure to new interfaces of administration components like intravenous (iv) bags, syringes, and tubing. In-use studies assess the potential impact on product quality by simulating drug handling throughout the defined in-use period. Considering the wide range of in-use conditions and administration components available globally, only limited guidance is available from regulators on expected in-use stability data. A working group reviewed and consolidated industry approaches to assess physicochemical stability of traditional protein-based biological products during clinical development and for commercial use. The insights compiled in this review article can be leveraged across the industry and encompass topics such as representative drug product material and administration components, testing conditions, quality attributes evaluated and respective acceptance criteria, applied quality standards, and regulatory requirements. These practices may help companies in the study design, and they may inform discussions with global regulators.& COPY; 2023 American Pharmacists Association. Published by Elsevier Inc. All rights reserved.
引用
收藏
页码:2332 / 2346
页数:15
相关论文
共 63 条
  • [1] Determination of critical quality attributes for monoclonal antibodies using quality by design principles
    Alt, Nadja
    Zhang, Taylor Y.
    Motchnik, Paul
    Taticek, Ron
    Quarmby, Valerie
    Schlothauer, Tilman
    Beck, Hermann
    Emrich, Thomas
    Harris, Reed J.
    [J]. BIOLOGICALS, 2016, 44 (05) : 291 - 305
  • [2] [Anonymous], CPMP/QWP/2934/99 Note for Guidance on In-Use Stability Testing of Human Medicinal Products 2001
  • [3] [Anonymous], 2003, INT C HARM Q1A R2 ST
  • [4] [Anonymous], Annex I - General safety and performance requirements
  • [5] Chapter II: Requirements Regarding Design and Manufacture
  • [6] [Anonymous], Scientific Opinion on the Safety of Medical Devices Containing DEHP-Plasticized PVC or Other Plasticizers on Neonates and Other Groups Possible at Risk
  • [7] [Anonymous], 2009, International Conference on Harmonization Q8 (R2) Pharmaceutical Development
  • [8] [Anonymous], 2002, International Conference on Harmonization M4Q (R1). The Common Technical Document for the Registration of Pharmaceuticals for Human Use: Quality
  • [9] [Anonymous], 2017, EMEA/CHMP/SWP/28367/07
  • [10] [Anonymous], USP <788>Particulate Matter in Injections